However, in the Capan-2 C1GALT1 KO model or the Capan-2 model treated with itraconazole, where MUC1 levels were increased, CAR-T cells with Tn-MUC1 bridge exhibited significantly more anti-tumor activity compared to the CD19-bridge (Fig. 2e, f and Supplementary Fig. 2e). This evidence concerns the gene CD19 and neoplasm.